Displaying 1 - 20 of 283
Federal Trade Commission Statement Concerning Brand Drug Manufacturers' Improper Listing of Patents in the Orange Book
Amgen Inc. and Horizon Therapeutics plc; Analysis of Agreement Containing Consent Order To Aid Public Comment
Amgen, Inc. and Horizon Therapeutics plc, In the Matter of
In August 2023, the FTC reached a proposed consent order with Amgen Inc. to address the potential competitive harm that would result from Amgen’s $27.8 billion acquisition of Horizon Therapeutics plc. As part of a nationwide settlement of their challenge to the acquisition, the FTC and attorneys general from six states – California, Illinois, Minnesota, New York, Washington, and Wisconsin – also dismissed the related federal court preliminary injunction action, allowing the transaction to proceed, with the conditions imposed by the order.
FTC Reaches Proposed Settlement with Surescripts in Illegal Monopolization Case
FTC Votes to Issue Statement Withdrawing Prior Pharmacy Benefit Manager Advocacy
FTC Announces Tentative Agenda for July 20 Open Commission Meeting
FTC Files Amicus Brief in Bystolic Antitrust Litigation Supporting Competition in the Hypertension Drug Market
FTC Further Expands Inquiry Into Prescription Drug Middlemen Industry Practices
FTC, DOJ Issue Summary on Joint Pharmaceutical Merger Analysis Workshop
FTC Deepens Inquiry into Prescription Drug Middlemen
Amgen Inc. and Horizon Therapeutics plc, FTC v.
Sage Chemical, Inc. et al. v. Supernus Pharmaceuticals, Inc. et al.
FTC Asks Federal Court to Hold ‘Pharma Bro’ Martin Shkreli in Contempt
Vyera Pharmaceuticals, LLC
The Federal Trade Commission and a group of seven state enforcers filed a complaint in federal district court against Vyera Pharmaceuticals, LLC, alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim. The Commission vote to issue the complaint was 5-0. The complaint was filed on Jan. 27, 2020, in the U.S. District Court for the Southern District of New York. In a Jan. 14, 2022 ruling, U.S. District Court Judge Denise Cote found Shkreli’s conduct “egregious, deliberate, repetitive, long-running, and ultimately dangerous.” Judge Cote banned Shkreli for life from the pharmaceutical industry.